NeuroMab™ Anti-Amyloid Beta 1-42 BBB Shuttle Antibody(NRZP-1022-ZP3665)

Figure 1 illustrates the selectivity of 8F5 for globulomers versus Aß(1-42) monomers, Aß(1-40) and sAPP. The selectivity factor for 8F5 can be calculated as the ratio between EC50 values (relative to Aß(1-42) monomer in HFIP 555.8/90.74=6.1; relative to Aß(1-42) monomer in NH4OH 1007 /90.74=11.1; vs. Aß(1-40) monomer 667.8/90.74=7.4 vs. sAPP >100)

Figure 2 illustrates the SDS-PAGE analysis of fibril-bound heavy and light chain antibodies (lanes 4, 6, 8) and the corresponding unbound free fractions (lanes 3, 5, 7) in the supernatant.

Figure 3 illustrates the novel object recognition index, the time spent on unknown objects versus familiar objects in three groups of APP transgenic mice (i.e., 6G1, 8F5, PBS) and a group of non-transgenic littermates (wild type).

Figure 4 shows the binding of different concentrations of antibodies to the neocortex cross-sections of Alzheimer's disease (AD) patients or aged APP transgenic mice.

Figure 4 illustrates that staining of Aβ parenchymal deposits (amyloid plaques) in an AD patient (RZ16) occurred only on 6G1 and the commercially available antibody 6E10, whereas 8F5 and 8C5 showed rather weak staining.

Figure 5 shows the binding of different concentrations of antibodies to the neocortex cross-sections of Alzheimer's disease (AD) patients or aged APP transgenic mice.

Figure 5 illustrates the quantification of the analysis of Aβ plaque staining in histological images using image analysis. Density values were calculated by subtracting the gray value of the background tissue from the gray value of the plaque (0% = no staining).